ASO Author Reflections: Is It Necessary to Routinely Clip and Localize the Biopsy-Proven Malignant Lymph Node?
- 25.03.2022
- ASO Author Reflections
Erschienen in:
- Verfasst von
- Anna Weiss, MD
- Tari A. King, MD
- Erschienen in
- Annals of Surgical Oncology | Ausgabe 6/2022
Auszug
Several large prospective trials, including the American College of Surgeons Oncology Group (ACOSOG) Z1071 trial,1 examined the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for patients presenting with cN1 disease. Collectively, the false-negative rates (FNR) in these trials ranged from 8 to 15%, and only one trial, SN FNAC,2 which required immunohistochemical staining of the SLN, met the primary end point of a FNR lower than 10%. However, eager to avoid the morbidity of axillary lymph node dissection (ALND) for patients with a pathologic complete response to NAC, the investigators examined subsets of patients for whom certain technical maneuvers resulted in an FNR lower than 10 %, including those in which mapping was performed with dual tracers, those with retrieval of at least three SLNs, and those in which the biopsied node was clipped and successful removal of the clipped lymph node was documented.3 …
Anzeige
- Titel
- ASO Author Reflections: Is It Necessary to Routinely Clip and Localize the Biopsy-Proven Malignant Lymph Node?
- Verfasst von
-
Anna Weiss, MD
Tari A. King, MD
- Publikationsdatum
- 25.03.2022
- Verlag
- Springer International Publishing
- Erschienen in
-
Annals of Surgical Oncology / Ausgabe 6/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681 - DOI
- https://doi.org/10.1245/s10434-022-11595-0
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
